Ruti Aga's Six-Year Ban: The Forgery, Not the Injection, Was the Case

Two years and four years. Six, added up. In the Ruti Aga case, the thing that speaks loudest is not the substance but that arithmetic. The Athletics Integrity Unit's statement landed on Thursday, and it dates the ban from 10 September — the same date her provisional suspension began. The first block is two years: a positive in-competition sample for methylprednisolone after a half marathon she won in China in March. The second block is four years: the medical prescription she produced during the investigation turned out to be forged. For me, the second block is the whole case. The second post is where the real story usually hides — here that post is the investigation file, and its heaviest word is ‘prescription’. The time she ran in that race appears in no statement. Without a start list and a results PDF, any line about the performance would be invention. I have worked off the results wire for years; here the wire is empty, and only a disciplinary decision exists. So the one safe sentence is that she won the race — which implies a World Athletics Label-tier elite field with in-competition testing, otherwise no AIU sample would exist at all. Aga is not a marginal name. She won the 2026 Tokyo Marathon and finished second three times at World Marathon Majors. She is a 2:18–2:20 marathoner — the tier that hovers around Major podiums and rarely appears in a straight championship race. Ethiopia's women's marathon depth is such that a full layer of world-record class sits above her; even a 2:18 performer is not automatically selectable. That context matters, because this case changes nothing on the track and a great deal in the governance column. The March half marathon in China belongs to the tier East African marathoners use as an income stop between Majors. Appearance fee decent, distance halved, load on the body lower. That same tier is now the AIU's highest-yield testing zone. The money and the testing are colliding inside the same races, and the collision will get sharper. Start with the technical error being repeated across coverage. Calling methylprednisolone a ‘prohibited steroid’ is wrong. It is a glucocorticoid, WADA Prohibited List class S9, not an anabolic steroid (S1). And under the current List, S9 drugs are prohibited in-competition only — by injection, oral or rectal route. A knee injection given as treatment is entirely legal out of competition. The violation arises only if residues are present in the sample taken at the race. So the timeline is the case. A road race's in-competition testing window opens at 23:59 the day before the race. A legitimate injection given days earlier can still be caught inside that window. Aga had a real defence available: records, route, timing. She closed the one path that remained open. I went back to the tape to find the moment everyone missed — in this file that moment is not in the race, it is on the paper. According to the AIU statement, she cited a knee injury and produced a prescription for the treatment. The clinic named on the prescription did not exist. The ‘doctor’ who wrote it was a family member with no medical registration. Asked about it, the explanation offered was that an old prescription pad from a former workplace had been used — and the clinic explicitly disowned any such pad. Three independent verification checks, three failures. The four-year tampering sanction rests on statements made during the interview, not on the document alone. Read the addition properly. Two years is the standard presence sanction where the substance is a Specified Substance and intent is unproven. Four years is the Code's standard tampering sanction. Which means the panel declined the no-significant-fault mitigation on the presence charge and treated the tampering as fully culpable. Backdating to 10 September is not relief; provisional suspension time is credited anyway. The March result and its prize money are almost certainly forfeit, though the statement does not say so. The 2026 Tokyo title and the three Major second places predate the violation, so they do not automatically fall. One more thing worth recording: there is no proven endurance benefit from a glucocorticoid. It reduces pain and swelling. That is why comparing this six-year ban to anabolic cases is meaningless — and why the decision will be quoted in two directions, as evidence of AIU rigour and as evidence of inconsistent enforcement against African road runners. Now the pivot where the accepted story becomes the second-most-important thing happening. The headline will read: ‘marathoner caught on steroids, out for six years.’ That sentence is wrong three ways — the substance class, the centre of the case, and the reason for the sanction. The real story is medical governance. The knee is the most common structural failure point in marathon running, and the pressure to mask it is sharpest on athletes whose income is appearance fees. An Indian athlete usually has a Railways or police job — a steady job letter is a bigger plot point than a personal best. An Ethiopian road runner has no such letter; her contract is the next race. A closed injury season means closed income. The cheapest, most available tool in that situation is a glucocorticoid injection. And the network around it is informal: no credentialed team physician, no TUE infrastructure, just a ‘doctor’ from the family circle. Follow the money, then follow the people it forgot — here the forgotten man is the family-member doctor. This is where I have to test my own favourite read. If this was knowing deception, what would the evidence look like? A real clinic record showing a long course of knee treatment, plus a TUE application, would make the paper-shortcut reading much harder to sustain. Conversely, if the same forged prescription turns up across several races, my governance-failure reading weakens and the deliberate-concealment reading strengthens. On present facts, the evidence points the other way: one prescription, built for one defence, and crude enough to break in three checks. Three things to watch. First, the appeal window — typically around 21 days from the reasoned decision — though a document-based tampering finding is hard to overturn. Second, the entourage the statement does not name: who asked for the prescription, who arranged it, whether a manager or agent was investigated, and whether the Ethiopian federation has said a single word — so far, silence. Third, and largest, the AIU's frontier is shifting from detection to document verification. On the day prescription checks become as routine in road racing as sample collection, the old prescription-pad trade closes. The question is how many names will have gone through that door by then.